KalVista Pharmaceuticals (KALV) Capital Expenditures (2014 - 2025)
KalVista Pharmaceuticals (KALV) reported Capital Expenditures of $290000.0 for Q3 2025, up 353.12% on a YoY basis from $64000.0 in Q3 2024, and up 67.63% sequentially from $173000.0 in Q2 2025.
KalVista Pharmaceuticals (KALV) Capital Expenditures (2014 - 2025) Analysis & Trends
KalVista Pharmaceuticals (KALV) has 12 years of Capital Expenditures data on file, last reported at $290000.0 in Q3 2025.
- For the quarter ending Q3 2025, Capital Expenditures rose 353.12% year-over-year to $290000.0; the trailing twelve-month figure through Jul 2025 stood at $592000.0 (up 492.0% YoY), and the FY2025 full-year result was $434000.0, up 933.33% from the prior year.
- Capital Expenditures rose to $290000.0 in Q3 2025, from $173000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $920000.0 in Q3 2022 to a low of -$252000.0 in Q2 2024.
- A 5-year average of $156000.0 and a median of $77500.0 in 2022 frame the typical range for Capital Expenditures.
- Peak annual rise in Capital Expenditures reached 3150.0% in 2024, while the deepest fall reached 465.22% in 2024.
- Tracing KALV's Capital Expenditures over 5 years: stood at $356000.0 in 2021, then slumped by 46.07% to $192000.0 in 2022, then slumped by 98.96% to $2000.0 in 2023, then surged by 3150.0% to $65000.0 in 2024, then jumped by 346.15% to $290000.0 in 2025.
- Business Quant data shows KALV's Capital Expenditures at $290000.0 in Q3 2025, $173000.0 in Q2 2025, and $65000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 43.25 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 786,000.00 |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn | 290,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 290,000.00 |
| Jul 31, 2025 | 290,000.00 |
| Apr 30, 2025 | 173,000.00 |
| Apr 30, 2025 | 173,000.00 |
| Oct 31, 2024 | 65,000.00 |
| Oct 31, 2024 | 65,000.00 |
| Jul 31, 2024 | 64,000.00 |
| Jul 31, 2024 | 64,000.00 |
| Apr 30, 2024 | -252,000.00 |
| Apr 30, 2024 | -252,000.00 |
| Jan 31, 2024 | 286,000.00 |
| Jan 31, 2024 | 286,000.00 |
| Oct 31, 2023 | 2,000.00 |
| Oct 31, 2023 | 2,000.00 |
| Jul 31, 2023 | 6,000.00 |
| Jul 31, 2023 | 6,000.00 |
| Apr 30, 2023 | 69,000.00 |
| Apr 30, 2023 | 69,000.00 |
| Jan 31, 2023 | 15,000.00 |
| Jan 31, 2023 | 15,000.00 |